Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122428 | 0.88 | MPO (0.39) | MPODHFRMAP4K4GAKNOS1 | |
| Morpholine SCHEMBL4526766 | 0.84 | MTOR (0.40) | MTOR | |
| Morpholine SCHEMBL4519198 | 0.81 | PDE4D (0.33) | MPODHFR | |
| SCHEMBL4108718 | 0.79 | CDK1 (0.39) | MPODHFRMAP4K4 | |
| SCHEMBL823714 | 0.79 | MAPT (0.40) | DHFRMAP4K4NOS1 | |
| SCHEMBL3608749 | 0.78 | NCF1 (0.38) | PDE5AMPODHFRMAP4K4MAPK14 | |
| SCHEMBL4113486 | 0.78 | TLR8 (0.42) | MPODHFRMAPK14NOS1 | |
| SCHEMBL4537635 | 0.78 | MAP4K4 (0.46) | MAP4K4 | |
| SCHEMBL3599474 | 0.78 | ADORA2A (0.49) | PDE5AMAP4K4MAPK14 | |
| SCHEMBL4520358 | 0.78 | TLR7 (0.48) | MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | PDE5A 1649/4885MPO 3990/4885DHFR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.